Eradication rate of *Helicobacter pylori* by classic triple therapy in Lebanon: Is it still effective?

Malak Hassan¹, Malak Noureddine²*, Farah Assi¹ and Zaher Houmani²

¹Internal medicine, Lebanese University, Faculty of Medical Sciences, Lebanon
²Gastroenterology Department, Najdeh Hospital, Nabatieh, Lebanon

**Abstract**

**Background:** *Helicobacter pylori* is considered the most common bacteria worldwide with a prevalence about 50% in developed countries and can reach up to 80-90% in developing countries. The first line agent for eradication of *H. pylori* has always been the classic triple therapy. However, recent data has shown the decline of the efficacy of this regimen due to antibiotics resistance. In Lebanon, due to the scarcity of data over the resistance rate of antibiotics and the efficacy of triple therapy, our study proposed a retrospective analysis of the eradication rate of *H. pylori* by classic triple therapy in the South of Lebanon between 2007 and 2014.

**Materials and methods:** A total of 168 patients were found eligible for the inclusion criteria in an 8-year data retrieval. The factors studied were (obesity, age, gender and smoking). The included patients received either one of the classic triple therapy regimens for 7, 10, or 14 days with no previous eradication, and followed up by at least one month after treatment with Urea breath test.

**Results:** 61.9% of patients were found to be sensitive to triple therapy, whereas 38.1% were resistant. There was no statistical significance between gender, age, and smoking history, method of diagnosis or type of triple therapy with *p* > 0.05. Adherence to treatment was good. No adverse effects were reported.

**Conclusions:** Our results showed suboptimal eradication rate by triple therapy. Thus, triple therapy should no more be considered the first line therapy for *H. pylori* eradication in Lebanon.
used the stool antigen to determine the prevalence rate of infection. The overall prevalence was 21% [22]. In 2012, a study designed by Naja et al. [23] to investigate the link between H. pylori infection and insulin resistance among Lebanese adults calculated the prevalence rate to be 52%, in a population of 308 individuals.

The Maastricht IV/Florence Consensus Report recommendations have been updated in 2017 concerning the management of H. Pylori. The triple therapy which includes proton pump inhibitors, clarithromycin, and amoxicillin or metronidazole has been the standard first-line regimen globally; however, recent data have shown that the success rate of this combination has been declining over the years, which has been directly linked to the increasing resistance to antibiotics most importantly to clarithromycin [24].

In 2008-2009 the overall resistance rate was reported to be 17.5% for clarithromycin, and 34.9% for metronidazole, according to a study designed on 2204 patients [25].

In Lebanon, a study conducted by Sharara et al. [26] in 2002 on 54 H. pylori isolates extracted by routine endoscopy in Beirut yielded results similar to those of Europe and USA concluding a low clarithromycin resistance rate of 4%, and a metronidazole resistance rate of 29.5%.

**Objective**

In countries with strong prevalence of resistance to macrolide, sequential therapy or bismuth quadruple therapy is being preferred over triple therapy. However, in Lebanon, due to the scarcity of data concerning resistance to antibiotics, no change in regimens has been proposed. Therefore, the purpose of this research is to determine the eradication rate of H. pylori in patients initially treated with classic triple therapy. The secondary objectives are to determine the association of the eradication rate with multiple demographic variables such as gender, smoking, obesity, past medical history and medication history. To identify a relation between the eradication rate and either the different types of triple therapy or the methods of diagnosis and finally to assess the results of the eradication rate yearly and on a four-year scale.

**Materials and methods**

Our study covers the areas of Nabatieh and Tyre. The main approach is to check the eradication rate of H. pylori in the past 8 years from the year 2007 till 2014 by classic triple therapy in a centered university hospital located in the south of Lebanon.

No formal sample size will be used in this research. Sample size depends on the number of eligible patients. All eligible patients will be included in this study.

The inclusion criteria include; patients aged between 10-80 years old, patients with first line treatment, patients who took triple therapy for 7, 10, or 14 days, patients who had Urea Breath Test after one month of treatment. The exclusion criteria the study will consider for 7, 10, or 14 days, patients who had Urea Breath Test after one month of treatment. The exclusion criteria the study will consider for 7, 10, or 14 days, patients who had Urea Breath Test after one month of treatment. The exclusion criteria the study will consider for 7, 10, or 14 days, patients who had Urea Breath Test after one month of treatment. The exclusion criteria the study will consider for 7, 10, or 14 days, patients who had Urea Breath Test after one month of treatment. The exclusion criteria the study will consider for 7, 10, or 14 days, patients who had Urea Breath Test after one month of treatment. The exclusion criteria the study will consider for 7, 10, or 14 days, patients who had Urea Breath Test after one month of treatment. The exclusion criteria the study will consider for 7, 10, or 14 days, patients who had Urea Breath Test after one month of treatment.

The most reported reasons of initial visit were epigastric pain in 137 patients (81.6%), constipation in 22 patients (13.1%), nausea in 19 patients (11.3%), anemia in 13 patients (7.7%) and diarrhea in 12 patients (7.1%). 89.3% of the patients were not on any medication. Eighteen patients (10.7%) out of 168 patients were on medication. Of whom, only 3 patients (1.8%) received proton pump inhibitors (PPIs).

Table 1 shows the different diagnostic methods used to detect the H. pylori infection. Of whom Urease rapid test (70.8%) is found to be the most preferred test followed by serology (23.8%). The number of patients treated with different triple therapy regimens are listed in Table 1.

The overall results showed a 61.9% eradication rate with classic triple therapy confirmed by urea breath test (Table 2) with a 38.1% resistance rate as seen in Figure 1.

**Table 1. Method of diagnosis and types of triple therapy**

<table>
<thead>
<tr>
<th>Diagnosis and type of triple therapy</th>
<th>N (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Serology</td>
<td>40 (23.8%)</td>
</tr>
<tr>
<td>Stool antigen</td>
<td>0 (0%)</td>
</tr>
<tr>
<td>Endoscopy: Pathology</td>
<td>5 (3%)</td>
</tr>
<tr>
<td>Endoscopy: Urease rapid test</td>
<td>119 (70.8%)</td>
</tr>
<tr>
<td>Urea Breath test</td>
<td>4 (2.4%)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>First line treatment</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Triple therapy: Amoxicillin, PPI, Clarithromycin</td>
<td>159 (94.6%)</td>
</tr>
<tr>
<td>Triple therapy: Amoxicillin, PPI, Metronidazole</td>
<td>7 (4.2%)</td>
</tr>
<tr>
<td>Triple therapy: Clarithromycin, PPI, Metronidazole</td>
<td>2 (1.2%)</td>
</tr>
</tbody>
</table>

**Table 2. Follow up and final result**

<table>
<thead>
<tr>
<th>Initial follow-up by Urea Breath test</th>
<th>N (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Negative</td>
<td>104 (61.9%)</td>
</tr>
<tr>
<td>Positive</td>
<td>64 (38.1%)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Follow-up test results</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Compliant to medication</td>
<td></td>
</tr>
<tr>
<td>Compliant</td>
<td>148 (100%)</td>
</tr>
<tr>
<td>Missing</td>
<td>20</td>
</tr>
</tbody>
</table>

| Patient is                           |       |
| Sensitive                            | 104 (61.9%) |
| Resistant                            | 64 (38.1%) |
Hassan M (2018) Eradication rate of Helicobacter pylori by classic triple therapy in Lebanon: Is it still effective?

Figure 2 shows that the eradication rate per year varied significantly from a 74%, 46%, 64%, 74%, 50%, 61%, 70%, and 43% in years 2007, 2008, 2009, 2010, 2011, 2012, and 2014 respectively.

The 4-year eradication rates from 2007 to 2010 and from 2011 till 2014 were 65% and 58% consecutively (Figure 3).

In Figure 4, the eradication rate was 63.5% in the amoxicillin, PPI, clarithromycin regimen, 42.9% in the amoxicillin, PPI, metronidazole regimen and 0% in the clarithromycin, PPI, metronidazole regimen, with no statistically significant differences ($p$-value = 0.105 > 0.05). Regimens including amoxicillin showed better eradication rates.

**Discussion**

Various studies have demonstrated the importance of $H. \text{ pylori}$ eradication in improving the outcomes of its related gastric diseases [12,27-29]. However, recent data has been signaling the decline in the efficacy of the first line triple therapy [24], as worldwide reported eradication rates have been reported to be less than the targeted 80%-cure rate for an infectious disease [30]. The results in our study have aligned with this current statement as they have demonstrated an eradication rate of less than 80% over the span of 8 years.

In our study 104/168 (61.9%) have witnessed a successful eradication with the triple therapy, whereas 64/168 (38.1%) have reported treatment failure. Studies in Kuwait and Kingdom of Saudi Arabia have also shown similar low-success rates of 68.6% [31], and 67.6% [32], respectively. Our four-year eradication rate between 2007 and 2010 was 65%, with a decrease to 58% between 2011 and 2014, despite offering no statistical significance ($p > 0.05$) this decrease can be considered recognizable, as a study in Turkey also reported drops in the efficacy of triple therapy similar to ours from a rate of 68.8% substantiated from 1999 till 2005 [33], to 57% in 2011 [34]. In years 2013 and 2014 the number of included patients is 6% and 4.2% respectively, this decline in included patients is mostly due to physicians switching to either quadruple or sequential therapy as first line agents following the international recommended guidelines for developing countries as a reference. The majority of our included patients (159/168) have received amoxicillin, clarithromycin, and a PPI of whom 101 (63.5%) were sensitive, and 58 (36.5%) were resistant. Of the remaining nine patients, seven have received amoxicillin, metronidazole, and a PPI of whom three (42.9%) were sensitive and four (57.1%) were resistant, and the remaining two patients received clarithromycin, metronidazole, and a PPI, of which both (100%) were resistant, this high resistance rate to the clarithromycin and metronidazole combination shows that amoxicillin-based regimen is mandatory for efficient eradication.
Epigastric pain has been observed as the number one reason of initial visit (81.6%), but many lower gastrointestinal symptoms are seen such as constipation, rectorrhagia, melena or anal pain. In these cases, _H. pylori_ was discovered accidentally during a regular endoscopy exam. No significant statistical variations (_p_ > 0.05) were noted between gender distributions, age, obesity, smoking history, method of diagnosis, and reason of initial visit. A study by Silva et al. [35] in 2001 assessing the effects of the variables: age, tobacco, gender, alcohol, non-steroidal inflammatory drugs and previous treatment, has also shown no statistical significance with _p_ > 0.05 with an exception for previously treated patients where the eradication rate was 53% in comparison with 76% for treatment-naïve patients [35]. The majority of our patients 94.5% were non-smokers. This has contributed in a positive aspect to our study, since smoking is one of the factors that lead to treatment failure as mentioned in a study by Namiot et al. [36] in 2000, where 142 _H. pylori_ positive patients were treated with two regimens, both of which smoking has decreased the efficacy of eradication to 53.7% [36].

Researches have shown a growing concern for the declining success of the triple therapy, and worldwide studies have been published to study the triple therapy eradication rates of _H. pylori_. Unsatisfactory results have been reported nationwide across south Europe and South Asia [37-39]. In the United States of America, a decline of 56%, and 50% in the success rates of clarithromycin-containing, and metronidazole-containing regimens, respectively, has been determined in a systemic review article [40].

To our knowledge, in Lebanon, only one study has been recently published comparing the efficacy of bismuth-containing quadruple therapy to 14-days sequential therapy with eradication rates favoring the sequential treatment (80% vs 50%). However, the number of patients included in the study was too small, in our opinion, to result in a significant difference [41].

**Conclusion**

The results have shown suboptimal eradication rate by triple therapy. The demonstrated decreasing efficacy of the triple therapy, compatible with numerous global results, calls for a similar change in the first-line regimens for the proper eradication of this pathogen. This necessitates carrying out more research, which addresses the extent of this collapsing efficacy of the triple therapy in different areas throughout Lebanon, and on different ethnicities and age groups. The cause of the high resistance rate has not been identified and could be from overconsumption, self-medication, or uncontrolled prescription of clarithromycin and/or metronidazole in Lebanon. Furthermore, patient education about _H. pylori_ Infection and the importance of adhering to medications, combined with a thorough follow up is recommended to ensure complete eradication and diminish resistance to antibiotics, as these are of vital importance to proper treatment. Moreover, larger prospective randomized controlled studies are needed in Lebanon to compare the different first line treatments. Thus, establishing our own guidelines regarding _H. pylori_ infection treatment.

**References**


3. Goni E, Franceschi F (2016) _Helicobacter pylori_ and extragastric diseases. _Helicobacter_ 21: 45-48. [Crossref]


11. Lehmann FS, Renner EL, Meyer-Wys B, Wilder-Smith CH, Mazzucchelli L, et al. (2000) _Helicobacter pylori_ and gastric erosions. Results of a prevalence study in asymptomatic volunteers. _Digestion_ 62: 82-86. [Crossref]


18. Malaty HM, Paykov V, Bykova O, Ross A, Graham DP, et al. (1996) _Helicobacter pylori_ and socioeconomic factors in Russia. _Helicobacter_ 1: 82-87. [Crossref]


Copyright: ©2018 Hassan M. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.